-- 週二，日本股市收低，此前日本央行維持政策利率在0.75%不變，並指出經濟前景存在更大的不確定性。 日經225指數下跌1.02%，或619.90點，收在59,917.46點。 三位理事反對這項決定，他們呼籲升息，這加劇了市場對政策可能轉變的預期。日本央行總裁上田一夫表示，由於中東衝突帶來的不確定性，實現央行預測的可能性已降低。 他指出，風險呈現雙向波動，經濟成長面臨下行壓力，而通膨面臨上行風險，尤其是在2026財年，這使得評估經濟和物價波動的持續時間和影響變得困難。 其他經濟新聞方面，日本3月失業率從2.6%上升2.7%，就業人數降至6,815萬人，失業人數增加至186萬人。 企業方面，電裝（TYO:6902）股價下跌約3%，此前該公司撤回了收購羅姆（TYO:6963）股份的提議，理由是缺乏支持且價值上漲空間有限。 日產汽車（TYO:7201）股價上漲約4%，此前該公司預測2025財年虧損將收窄，預計每股虧損157.42日元，淨虧損5,500億日元，同時銷售額略有成長。 出光興產（TYO:5019）股價上漲約3%，此前有報導稱，該公司將透過繞過霍爾木茲海峽的航線向越南供應約400萬桶原油。
Related Articles
International
U.S. Energy Production Climbs 3% YoY in January, EIA Reports
U.S. primary energy production rose 3% year over year in January to 9.1 quadrillion British thermal units, the U.S. Energy Information Administration said in its Monthly Energy Review released Monday.Total fossil fuels production in January was made up of 46% dry natural gas, 31% crude oil, 12% crude oil and 11% natural gas plant liquids, the EIA reported.Total renewable energy production was composed of 56% biomass, 20% wind, 12% hydroelectric power, 11% solar and 1% geothermal energy, according to the agency.U.S. natural gas plant liquids production was 7% higher in January than in the year-ago month. Dry natural gas production and renewable energy production each climbed 4%. Nuclear electric power production and coal production each increased 2%. Crude oil production rose 1%.
$CLX1$LCOX1$NGV1$UNG$UNL$USO
Asia
CanSino Biologics Widens Loss in Q1
CanSino Biologics (HKG:6185, SHA:688185) widened its attributable loss in the first quarter of 2026 to 40.4 million yuan from 11.5 million yuan a year prior, according to a Tuesday Hong Kong bourse filing.Loss per share was 0.16 yuan, compared with 0.05 yuan in the corresponding period of the previous fiscal year.Operating revenue jumped 39% to 190.3 million yuan from 137.2 million yuan in the year-ago period, amid the company's expanding commercial product portfolio, increasing overseas presence, and robust sales of hte MCV4 vaccine.The vaccine manufacturer attributed the wider loss to a higher operating cost; a rise in selling, administrative, and R&D expenses; and a lower other income related to government grants and international funding support.
$HKG:6185$SHA:688185
Japan